Catalyst Biosciences Revenue and Competitors

Claim your profile

Location

$301.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Catalyst Biosciences's estimated annual revenue is currently $6k per year.(i)
  • Catalyst Biosciences received $115.0M in venture funding in February 2018.
  • Catalyst Biosciences's estimated revenue per employee is $136
  • Catalyst Biosciences's total funding is $301.3M.

Employee Data

  • Catalyst Biosciences has 44 Employees.(i)
  • Catalyst Biosciences grew their employee count by -51% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. We used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. Learn more about Our Hemophilia Program. A protease is an enzyme that cleaves target proteins. Learn more about Proteases.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$301.3M

Total Funding

44

Number of Employees

$6k

Revenue (est)

-51%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Catalyst Biosciences News

2022-04-20 - -$0.56 Earnings Per Share Expected for Catalyst Biosciences, Inc ...

Wall Street analysts expect that Catalyst Biosciences, Inc. (NASDAQ:CBIO – Get Rating) will announce earnings per share (EPS) of ($0.56) for...

2022-03-30 - Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 ...

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and...

2022-03-30 - Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 ...

Catalyst is a research and clinical development biopharmaceutical company focused on developing protease therapeutics to address unmet medical...

2021-11-15 - Catalyst Biosciences : Investor presentation 4.7 MB

CATALYST BIOSCIENCES Corporate Overview 15 November 2021 © Catalyst Biosciences Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncertainti ...

2021-09-28 - Catalyst Biosciences : Investor presentation 3.1 MB

Nasdaq: CBIO CATALYST BIOSCIENCES Corporate Overview 28 September 2021 CatalystBiosciences.com Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risk ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8M44144%N/A
#2
$2.9M4510%N/A
#3
$7M4555%N/A
#4
$7.6M47-2%N/A
#5
$7.4M480%N/A

Catalyst Biosciences Funding

DateAmountRoundLead InvestorsReference
2004-10-29$10.3MASofinnova VeArticle
2006-02-10$30.0MBMorgenthaler VenturesArticle
2008-12-04$40.4MCEssex Woodlands Health VentureArticle
2012-01-09$7.0MUndisclosedPfizerArticle
2017-04-10$20.7MUndisclosedLadenburg Thalmann & Co. IncArticle
2017-12-22$10.5MUndisclosedJonesTrading Institutional Services LLCArticle
2018-02-14$115.0MUndisclosedJonesTrading Institutional Services LLCArticle